You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

JEMPERLI ▼ (dostarlimab) logo

Product menu

Let their light shine with Jemperli ▼

JEMPERLI is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.1

Image of Black Woman gardening

JEMPERLI + CP demonstrates a statistically significant (p<0.0001) and clinically meaningful PFS benefit vs placebo + CP in dMMR/MSI-H primary advanced or recurrent EC1,2

DISCOVER THE RUBY TRIAL
JEM_Patient_Campaign_Kitchen_White

Jemperli is an immunotherapy indicated in combination with carboplatin and paclitaxel (CP) for patients with advanced or recurrent dMMR/MSI-H endometrial cancer who have progressed on or following platinum-based chemotherapy, in whom it demonstrated durable efficacy for more than 2 years1

Explore Clinical Data
Image of percentage of dMMR/MSI-H in EC

of endometrial cancers are dMMR/MSI-H3

dMMR/MSI-H is an important biomarker that can help to personalise endometrial cancer treatment6

Guidelines recommend testing patients with endometrial cancer for dMMR/MSI-H4,5

Response Rate Icon

Jemperli Efficacy

JEMPERLI + CP demonstrates a statistically significant (p<0.0001) and clinically meaningful PFS benefit vs placebo + CP in dMMR/MSI-H primary advanced or recurrent EC2

VIEW THE EVIDENCE >
Safety Icon

Jemperli Safety Profile

JEMPERLI + CP offers a generally manageable safety profile, consistent with the known profiles of individual components, for up to 3 years of follow-up1,2,6

EXPLORE THE DATA >
Dosing and Administration Icon

Dosing & Treatment Management

The recommended dose of JEMPERLI as part of combination therapy is 500 mg every 3 weeks for 6 cycles followed by 1000 mg every 6 weeks thereafter1

LEARN MORE >
Explore the Resource Library

Jemperli Patient Support Material

Dosing and Admin Resources

Do you have questions about how JEMPERLI can support your patients? 
Contact a GSK Representative

SEND AN EMAIL

Find out more about JEMPERLI

DOWLOAD API

Indications

JEMPERLI is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.

JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.

Footnotes

CP, carboplatin/paclitaxel; dMMR, mismatch repair deficient; EC, endometrial cancer; MSI-H, microsatellite instability-high.

References

  1. Jemperli (dostarlimab) Summary of product characteristics January 2025 https://www.medicines.ie/ Last accessed April 2025.
  2. Mirza MR, et al. Dostarlimab for primary advanced recurrent endometrial cancer. N Eng J Med. 2023;388(23):2145-2158
  3. Green AK, et al. A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book. 2020;40:1-7
  4. Oaknin A, et al. Endometrial Cancer. ESMO Clinical practice Guidelines for diagnosis, treatment and follow up. Ann oncol. 2022;33(9):860-8
  5. National Institute for Health and Care Excellence. DG42. Testing strategies for Lynch syndrome in people with endometrial cancer. October 2020. Available from https://www.nice.org.uk/guidance/dg42 Accessed March 2025
  6. Powell MA, et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomised ENGOT-EN6/GOG-3031/RUBY Trial. Annals of Oncology (2024)

POM. Further information is available from GlaxoSmithKline (Ireland) Ltd

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com/.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

PM-IE-DST-WCNT-240002 | May 2025